This nationwide Danish register-based cohort study followed 65,630 individuals with incident schizophrenia spectrum disorders from 1998-2023, analyzing over 26.9 million person-weeks of data. The study examined antipsychotic exposure using both within-subject (time-varying) and between-subject (baseline) comparisons, with productive engagement (employment or education) as the primary outcome. The overall productive engagement rate was 48.2% across the cohort.
Results showed time-dependent associations: during the acute phase (0-2 years), antipsychotic exposure was associated with reduced engagement rates (HR 0.908); during consolidation (2-5 years), exposure was associated with reduced engagement (HR 0.946); and during maintenance (5+ years), exposure showed a small positive association (HR 1.019). The between-subject model yielded a subdistribution hazard ratio of 1.002 (95% CI 0.988-1.015), indicating no clear overall association when comparing individuals.
Safety and tolerability data were not reported. A key limitation identified was that integration of hospital pharmacy data revealed 6.1% exposure misclassification in studies relying solely on community records, potentially affecting accuracy. As an observational study, these findings represent associations rather than causal relationships, and the within-subject analysis was used to reduce time-invariant confounding. The practice relevance was not explicitly reported, but clinicians should recognize these findings as population-level averages that may obscure individual patient trajectories and phase-specific dynamics.
View Original Abstract ↓
Background. Antipsychotic medications are recommended for schizophrenia spectrum disorders, yet their long-term effects on functional recovery remain unclear, with conflicting evidence often derived from between-subject comparisons vulnerable to confounding by indication. Methods. We conducted a nationwide register-based cohort study of 65,630 individuals with incident schizophrenia spectrum disorders in Denmark (1998-2023). We modelled antipsychotic exposure against "productive engagement" (employment or education). We used two analytical approaches: (1) within-subject stratified Cox models with time-varying covariates to eliminate time-invariant confounding; and (2) Fine-Gray competing risks models with baseline exposure, accounting for mortality and emigration. Results. Over 26.9 million person-weeks, the overall productive engagement rate was 48.2%. Integration of hospital pharmacy data revealed 6.1% exposure misclassification in studies relying solely on community records. The primary within-subject analysis revealed significant temporal heterogeneity: medication use was associated with reduced engagement rates in the acute (0-2 years: HR 0.908) and consolidation phases (2-5 years: HR 0.946), but reversed to a small positive association in the maintenance phase (5+ years: HR 1.019). The between-subject Fine-Gray model, which estimates cumulative engagement probabilities, yielded an SHR of 1.002 (95% CI 0.988-1.015), a population-level average that obscured these phase-specific dynamics. Conclusions. Antipsychotic pharmacotherapy exerts a time-dependent, biphasic impact on vocational recovery. We identified a window of vulnerability during the post-acute "consolidation" phase (years 2-5) where treatment is associated with a transient reduction in productive engagement, before becoming protective after five years. These findings challenge the assumption that symptomatic stability automatically facilitates functional reintegration.